SCHEMBL4294539

SCHEMBL4294539

CC(C)(C)C(=O)Nc1ncc(-c2cncc(C(N)=O)c2)s1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 8/20 0.48
CDK7 P50613 4/20 0.42
KDR P35968 2/20 0.41
POLQ O75417 1/20 0.41
OTUD7B Q6GQQ9 1/20 0.41
MKNK1 Q9BUB5 2/20 0.39
MKNK2 Q9HBH9 2/20 0.39
SCD O00767 1/20 0.38
CCNB2 O95067 1/20 0.38
CCNE2 O96020 1/20 0.38
CDK1 P06493 1/20 0.38
CDK4 P11802 1/20 0.38
CCNB1 P14635 1/20 0.38
CCND1 P24385 1/20 0.38
CCNE1 P24864 1/20 0.38
CDK2 P24941 1/20 0.38
CCNB3 Q8WWL7 1/20 0.38
PIK3CA P42336 1/20 0.38
CYP11B1 P15538 1/20 0.38
CYP11B2 P19099 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4294396 0.82 NPC1 (0.47) CHEK1CDK7KDRMKNK1SCD
SCHEMBL3176327 0.77 LIMK1 (0.52) KDRMKNK1SCDCCNE1CDK2
SCHEMBL3169992 0.76 PIK3CA (0.46) KDRMKNK1MKNK2SCDCCNB2
SCHEMBL10079021 0.73 KDR (0.53) KDRMKNK1SCDCCNE1CDK2
SCHEMBL25682573 0.73 CHEK1 (0.46) CHEK1CDK7KDROTUD7BMKNK1
SCHEMBL4292749 0.73 KDR (0.46) CHEK1CDK7KDRMKNK1SCD
SCHEMBL594373 0.71 KDR (0.50) KDRMKNK1SCDCCNE1CDK2
SCHEMBL12529432 0.70 MKNK1 (0.47) CHEK1MKNK1MKNK2CYP11B1CYP11B2
SCHEMBL3901196 0.70 ATAD2 (0.45) CHEK1CDK7KDRSCDCDK1
SCHEMBL14817172 0.69 MKNK1 (0.51) CHEK1POLQMKNK1MKNK2CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233896-A1 Inhibitors of checkpoint kinases MERCK SHARP & DOHME CORP. 2009-09-17 US disclosed
US-20090233896-A1 Inhibitors of checkpoint kinases MERCK SHARP & DOHME CORP. 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233896-A1 Inhibitors of checkpoint kinases CHEK1, CHEK2, PLK1 CHEK1 1/4885CDK7 39/4885KDR 3027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.